Axa
RGLS

Axa’s Regulus Therapeutics RGLS Stock Holding History

Axa’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-8,884
Closed -$2.4M – 1313
2016
Q4 		$2.4M Buy
8,884
+171
+2% +$55.6K 0.01% 733
2016
Q3 		$3.45M Buy
8,713
+3
+0% +$1.23K 0.02% 647
2016
Q2 		$3.02M Buy
8,710
+1,264
+17% +$905K 0.01% 662
2016
Q1 		$6.19M Sell
7,446
-120
-2% -$95.5K 0.03% 502
2015
Q4 		$7.92M Sell
7,566
-159
-2% -$159K 0.03% 446
2015
Q3 		$6.06M Buy
+7,725
New +$7.93M 0.02% 516

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Axa's RGLS Position: Q1 2017 in Review

Axa sold out of Regulus Therapeutics (RGLS) in Q1 2017, closing a stake of 8,884 shares — an estimated $2.4M sold.

Axa first reported a position in RGLS in Q3 2015 and held it in 6 quarters. The position peaked at $7.92M in Q4 2015. 58 funds tracked by Wall St. Rank hold RGLS as of Q1 2017.

  • Axa reported no remaining Regulus Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Axa sold 8,884 Regulus Therapeutics shares in Q1 2017, an estimated $2.4M.
  • Axa first reported a position in Regulus Therapeutics in Q3 2015 and held it in 6 quarters.
  • Axa's Regulus Therapeutics position peaked at $7.92M in Q4 2015.
  • 58 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2017.

Based on Axa's 13F filing for Q1 2017, filed 11 May 2017.